At a glance
ClinicalIndex Comparison RecordN/ACompleted· 221 enrolled
Drug / intervention
Implantation of the Tendril 2088 lead in the LBBAdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Left Bundle Branch Area Pacing (LBBAP) Data Collection Registry
In Brief
An observational study evaluating Implantation of the Tendril 2088 lead in the LBBA for Bradycardia and 5 related conditions. Completed, enrolled 221 participants across 11 sites in 5 countries.
Detailed Summary
The purpose of this registry is to evaluate the safety and effectiveness of LBBA pacing/sensing in patients already implanted with the Tendril STS 2088 lead.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBradycardia, Sinus Node Dysfunction, Heart Block, Syncope, Cardiomyopathies, Heart Failure
CountriesFrance, India, Italy, Singapore, United States
Collaborators--
Timeline
N/ACompletedFinished
202420252026
Enrollment StartApr 2023
First PostedJun 2023
Primary CompletionJul 2023
TodayJul 2026
First PostedJun 2, 2023
Enrollment StartApr 25, 2023
Primary CompletionJul 11, 2023
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 3.1 years ago
Interventions
Implantation of the Tendril 2088 lead in the LBBAdevice
Conduction system pacing is achieved by delivering a pacing stimulus to the Left Bundle Branch area of the heart with Abbott's Tendril 2088 lead.